The effects of benzodiazepine-receptor antagonists and partial inverse agonists on acute hepatic encephalopathy in the rat

Gastroenterology

Volumn 101, Issue 3, 1991, Pages 772-781

  Bosman, Diederik K ^a   Van Den Buijs, Constantinus A C G ^a   De Haan, Jan G ^a   Maas, Martinus A W ^a   Chamuleau, Robert A F M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 8 AZIDO 5,6 DIHYDRO 5 METHYL 6 OXO 4H IMIDAZO[1,5 A][1,4]BENZODIAZEPINE 3 CARBOXYLIC ACID ETHYL ESTER; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; FLUMAZENIL; SARMAZENIL;

ANIMAL MODEL; ARTICLE; BEHAVIOR; HEPATIC ENCEPHALOPATHY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMAL; AZIDES; BENZODIAZEPINES; BENZODIAZEPINONES; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, VISUAL; FLUMAZENIL; HEPATIC ENCEPHALOPATHY; MALE; RATS; RATS, INBRED STRAINS; RECEPTORS, GABA-A;

EID: 0025743786     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/0016-5085(91)90538-V     Document Type: Article

References (50)

1. Perspectives in hepatic encephalopathy
2. Hepatic encephalopathy. The mechanism of hepatic coma
3. Hepatic encephalopathy
4. GABA receptor multiplicity
5. Benzodiazepine-GABA receptor-ionophore complex
6. Hepatic encephalopathy and the gammaaminobutyric acid neurotransmittor system
7. Gammaaminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic failure
8. Metabolism of the inhibitory neurotransmittor gamma-aminobutyric acid in a rabbit model of fulminant hepatic failure
9. Increased blood brain transfer in a rabbit model of acute liver failure
10. Hepatic Encephalopathy
11. Hepatic encephalopathy: lack of changes of gamma-aminobutyric acid content in plasma and cerebrospinal fluid
12. Blood-brain permeability in galactosamine-induced hepatic encephalopathy. No evidence for increased GABA-transport
13. Overestimation of gamma-aminobutyric acid in patients with hepatic encephalopathy by the gamma-aminobutyric acid radio-receptor assay
14. Experimental hepatic encephalopathy: changes in the binding of gamma-aminobutyric acid
15. Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy?
16. Further evidence that hepatic encephalopathy in the galactosamine rabbit model may be mediated by an endogenous benzodiazepine compound
17. Differential responsiveness of cerebellar purkinje neurons to GABA and benzodiazepine receptor ligands in an animal model of hepatic encephalopathy
18. “Endogenous” benzodiazepine activity in body fluids of patients with hepatic encephalopathy
19. Amelioration of hepatic encephalopathy by pharmacologic antagonism of the GABA-benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure
20. Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands
21. Supersensitivity of benzodiazepine receptors in hepatic encephalopathy due to fulminant hepatic failure in the rat: reversal by a benzodiazepine antagonist
22. Selective antagonists of benzodiazepines
23. Improvement of hepatic encephalopathy treated with Flumazenil
24. Treatment of hepatic encephalopathy with the benzodiazepine antagonist Flumazenil
25. Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans
26. Hepatic encephalopathy and benzodiazepine receptor ligands
27. Recent advances in the molecular pharmacology of benzodiazepine receptors and in the structure-activity relationships of their agonists and antagonists
28. Hepatic coma: studies on the target organ
29. Ro 15-4513 partial inverse agonism at the BZR and interaction with ethanol
30. Correlation between electro encephalographic and biochemical indices in acute hepatic encephalopathy
31. A computerised EEG analysis system for small laboratory animals
32. Metabolic activity of microcarrier attached liver cells after intraperitoneal transplantation during severe liver insufficiency in the rat
33. Pharmacokinetic studies on Rol5-1788, a benzodiazepine receptor ligand, in the brain of the rat
34. Assessment of hepatic encephalopathy with visual evoked potentials compared with conventional methods
35. Visual evoked potential; a tool in the diagnosis of hepatic encephalopathy?
36. Hepatic encephalopathy: application of visual evoked responsese to test hypothesis of its pathogenesis in rats
37. Objective measurements of hepatic encephalopathy by means of spectral analysis and evoked responses
38. Pharmacokinetics of benzodiazepine antagonist Ro15-1788 in cirrhotic patients with moderate or severe liver dysfunction
39. In vivo studies of GABAergic effects in experimental hepatic encephalopathy
40. A benzodiazepine antagonist does not alter the course of hepatic encephalopathy or neuronal gamma-aminobutyric acid (GABA) binding
41. Plasma GABA, GABA-like activity and the brain GABA benzodiazepine receptor complex in rats with chronic hepatic encephalopathy
42. Hepatic encephalopathy in cirrhotic and portacaval shunted dogs: lack of changes in brain GABA uptake, brain GABA levels, brain glutamic acid decarboxylase activity and brain postsynaptic GABA receptors
43. Decreased brain GABA binding in a model of fulminant hepatic failure: evidence conflicting with the GABA hypothesis for hepatic encephalopathy (abstr)
44. Studies of central and peripheral type benzodiazepine receptors in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy
45. Brain cortex amino acids during acute hepatic encephalopathy in the rat studied by brain dialysis (abstr)
46. A receptor complex in an experimental model of hepatic encephalopathy: evidence for elevated levels of an endogenous receptor ligand
47. 1H-NMR spectroscopy during acute hepatic encephalopathy
48. Evidence for a functional imbalance between central GABA-ergic and Glutamergic neurotransmission in portal-systemic encephalopathy